ALACHUA, Fla.–(BUSINESS WIRE)–RTI Biologics Inc. (RTI) (Nasdaq:RTIX – News), a leading processor of orthopedic and other biologic implants, reported operating results for the second quarter ended June 30, 2009 as follows:
Quarterly Highlights:
> Record quarterly revenues of $41.1 million
> Net income of $1 million, or $0.02 per fully diluted share
> Launched five new spine implants with four distributors, including initial implants launched with our newest distributor, Aesculap
> Launched initial dermis implant with ENTrigue for use in the otolaryngology market
> Record quarterly revenue in sports medicine
> Increased number of direct biologic representatives by 6 to a total of 35
> Record revenue of $3.0 million in domestic hernia repair, an increase of more than 140 percent over the previous year’s period
